The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

LOS ANGELES - Acelyrin Inc. (NASDAQ: SLRN), a biopharmaceutical company specializing in immunology treatments, has implemented a stockholder rights plan following Tang Capital Partners ...

Tang Capital controls 8.8%, or 8.82 million shares, of Acelyrin, according to a U.S. Securities and Exchange Commission filing. The San Diego-based firm owns 9.6%, or 5.86 million shares ...

Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.

Equities research analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for Fate Therapeutics in a ...

Equities research analysts at StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free ...